Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
INMD vs AHCO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AHCO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)
AHCO Overall Winner
6-Pillar Tally: INMD 3 – 3 AHCO
Matrix Metrics: INMD 4 – 6 AHCO
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over InMode Ltd. (INMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). INMD carries a Unified Composite Score of 37.6/100 (SELL) at $12.42 (9.2x Forward P/E, 17.9% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin).
- Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.1); meanwhile AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About INMD vs AHCO
INMD
InMode Ltd. Ordinary Shares
$12.42
-2.2% 1D
Market Cap
$730.8M
TTM Revenue
$374M
Forward P/E
9.2x
Beta / 30D Vol
0.61β · 35% Vol
Unified Composite Score
37.6
SELL
Tech 25.0
Fund 45.0
Flow 57.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
AHCO
Head-to-Head Winner
AdaptHealth Corp. Common Stock
$7.20
-0.69% 1D
Market Cap
$989.8M
TTM Revenue
$3.44B
Forward P/E
7.8x
Beta / 30D Vol
0.17β · 67% Vol
Unified Composite Score
45.2
HOLD
Tech 29.0
Fund 46.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (INMD 3 – 3 AHCO)
1. Valuation Multiples
AHCO
Forward P/E
9.2x
7.8x
Trailing P/E
10.8x
7.8x
PEG Ratio
0.83x
N/M
EV / Revenue
0.9x
0.9x
2. Growth & Scale
AHCO
Revenue Growth (YoY)
-1.1%
+10.9%
Earnings Growth (YoY)
-5.9%
+6.7%
TTM Revenue (USD)
$374M
$3.44B
Market Cap
$730.8M
$989.8M
3. Profitability & Quality
INMD
Gross Margin
76.6%
18.2%
Operating Margin
17.9%
3.8%
Net Profit Margin
20.0%
-11.8%
Return on Equity (ROE)
11.4%
-28.4%
4. Balance Sheet & Cash Flow
INMD
Cash Generation (TTM)
$69M
$82M
Cash Flow Margin
18.6%
2.4%
Net Cash / Leverage
$394M Net Cash
$1.97B Net Debt (1.67x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AHCO
Options Structure Phase
CONSOLIDATION
SURGE
Current IV / %ile
44.2% (12th %ile)
66.9% (12th %ile)
Put/Call OI Skew
0.90x (Balanced)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
INMD
OpEx & R&D Intensity
58.7% of Rev ($219M)
14.4% of Rev ($495M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: INMD (4) vs AHCO (6)| Institutional Metric | INMD | AHCO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $730.8M | $989.8M | AHCO | |
| Trailing P/E Ratio | 10.8x | 7.8x | AHCO | |
| Forward P/E Ratio | 9.2x | 7.8x | AHCO | |
| Revenue Growth (YoY) | -1.1% | +10.9% | AHCO | |
| Operating Margin (TTM) | 17.9% | 3.8% | INMD | |
| Net Profit Margin | 20.0% | -11.8% | INMD | |
| Return on Equity (ROE) | 11.4% | -28.4% | INMD | |
| 52-Week Range Position | 0% ($12–$17) | 24% ($5–$13) | AHCO | |
| Beta / 30D Volatility | 0.61β · 35% Vol | 0.17β · 67% Vol | INMD | |
| Unified Institutional Score | 37.6 / 100 (SELL) | 45.2 / 100 (HOLD) | AHCO | |
| Trailing 12M Revenue (USD) | $374M | $3.44B | Scale | |
| Gross Profit Margin (TTM) | 76.6% | 18.2% | Quality | |
| PEG Ratio & EV / Revenue | 0.83x PEG · 0.9x EV/Rev | N/M PEG · 0.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $69M ($394M Net Cash) | $82M ($1.97B Net Debt (1.67x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AHCO +28.29 pp
3M Horizon
AHCO +45.64 pp
6M Horizon
INMD +21.49 pp
1Y Horizon
INMD +9.28 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INMD Revenue | AHCO Revenue | INMD Op. Margin | AHCO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $100M | $350M | 23.5% | 9.0% | INMD |
| FY2019 | $160M | $530M | 38.1% | 5.5% | INMD |
| FY2020 | $210M | $1.06B | 35.3% | 6.8% | INMD |
| FY2021 | $360M | $2.45B | 46.8% | 9.2% | INMD |
| FY2022 | $450M | $2.97B | 43.6% | 6.4% | INMD |
| FY2023 | $490M | $3.20B | 39.8% | -18.7% | INMD |
| FY2024 | $390M | $3.26B | 28.5% | 8.1% | INMD |
| FY2025 | $370M | $3.24B | 23.0% | 2.8% | INMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
INMD
CONSOLIDATION
Current IV
44.2%
IV Percentile
12th %ile
Put/Call OI Skew
0.90x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact INMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AHCO
SURGE
Current IV
66.9%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
INMD Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
58.7% of Rev ($219M)
90D Engineering Disclosures
0 Published
AHCO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
14.4% of Rev ($495M)
90D Engineering Disclosures
0 Published
Investor FAQ INMD vs AHCO Key Questions & Quantitative Answers
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over InMode Ltd. (INMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). INMD carries a Unified Composite Score of 37.6/100 (SELL) at $12.42 (9.2x Forward P/E, 17.9% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.1); meanwhile AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHCO leads the Growth & Scale pillar: INMD posts -1.1% YoY revenue growth and -5.9% YoY earnings growth on $374M TTM revenue (76.6% gross margin, 17.9% operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INMD cumulative revenue shifted +270.0% while AHCO shifted +825.7%. In operating R&D and SG&A reinvestment, INMD deploys 58.7% of Rev ($219M) (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.
AHCO screens cheaper on headline valuation multiples. INMD trades at 9.2x Forward P/E, 10.8x Trailing P/E, 0.83x PEG, and 0.9x EV/Revenue (18.6% FCF margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INMD (11.4% ROE) versus AHCO (-28.4% ROE) capital efficiency.
In options market volatility and institutional positioning, INMD carries 44.2% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.90x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 35% Vol realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AHCO vs INMD · Reverse Pair
INMD vs PGNY
· Sector Peer
INMD vs DOCS
· Sector Peer
INMD vs APPS
· Sector Peer
AHCO vs OPCH
· Sector Peer
AHCO vs ADUS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem